Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 54 SAMCO
2024-517362-41-00Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of avelumab in colorectal cancer (CRC) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Radiographic progression-free survival (PFS). Started Sep 2024; status: completed.
02
Drugs
avelumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-517362-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517362-41-00.